Related Experiment Video

Updated: Aug 8, 2026

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis
08:48

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis

Published on: March 19, 2019

Current advances in antifungal targets and drug development

Sandeep Sundriyal1, Rohit K Sharma, Rahul Jain

  • 1Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar, Punjab 160 062, India.

Current Medicinal Chemistry
|May 23, 2006
PubMed

Insights

Novel antifungal drug discovery is crucial due to rising fungal infections and resistance to existing treatments like Amphotericin B. This review highlights new targets and molecules to combat these challenges.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Systemic fungal infections are increasing, particularly in immunocompromised individuals.
  • Current antifungal therapies, like Amphotericin B, face challenges including toxicity, efficacy, cost, and emerging resistance.
  • There is a critical need for new antifungal agents with novel mechanisms of action.

Purpose of the Study:

  • To review recent advancements in the discovery of novel antifungal drug targets.
  • To survey investigational antifungal molecules and their mechanisms of action.
  • To address the demand for new antifungal therapies with improved safety and efficacy profiles.

Main Methods:

  • Literature review of recent scientific publications.
  • Analysis of emerging antifungal drug targets and chemical classes.
  • Evaluation of preclinical and clinical data on investigational antifungal agents.

Main Results:

  • Identification of several promising novel antifungal targets.
  • Characterization of diverse classes of investigational antifungal compounds.
  • Assessment of the potential of these new agents to overcome existing limitations.

Conclusions:

  • Recent research offers promising avenues for developing next-generation antifungal drugs.
  • Targeting novel pathways and utilizing diverse chemical scaffolds are key strategies.
  • Continued investment in antifungal drug discovery is essential to combat resistant fungal infections.

More Related Videos

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Quantifying the Antifungal Activity of Peptides Against Candida albicans06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...